Revolution Medicines CMO sells 2,073 company shares

Revolution Medicines, Inc. Chief Medical Officer Wei Lin reported an open-market sale of 2,073 shares of common stock on March 17, 2026 at an average price of $99.4804 per share.

Rhea-AI Filing Summary

Revolution Medicines, Inc. Chief Medical Officer Wei Lin reported an open-market sale of 2,073 shares of common stock on March 17, 2026 at an average price of $99.4804 per share. The transaction was made under a pre-arranged Rule 10b5-1 instruction letter adopted on December 23, 2024 to satisfy tax withholding obligations upon the vesting of restricted stock units after March 15, 2025. Following this sale, Lin holds 101,366 shares directly, which the disclosure states includes 62,050 restricted stock units.

Insider Trade Summary 10b5-1

Net Seller: 2,073 shares

Net Sell 1 txn

Insider Wei Lin

Role Chief Medical Officer

Sold 2,073 shs ($206K)

Type	Security	Shares	Price	Value
Sale	Common Stock	2,073	$99.4804	$206K

Holdings After Transaction: Common Stock — 101,366 shares (Direct)

Footnotes (2)

1. F1. Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on December 23, 2024 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units ("RSUs") after March 15, 2025.
2. F2. Includes 62,050 RSUs.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did RVMD Chief Medical Officer Wei Lin report?

Wei Lin reported selling 2,073 shares of Revolution Medicines common stock. The open-market sale occurred on March 17, 2026 at an average price of $99.4804 per share, according to the Form 4 insider trading disclosure for RVMD.

Why did RVMD executive Wei Lin sell 2,073 shares of stock?

The sale was made to satisfy Wei Lin’s tax withholding obligation on vested restricted stock units. It was executed under a pre-arranged Rule 10b5-1 instruction letter adopted on December 23, 2024, covering RSUs vesting after March 15, 2025.

Was Wei Lin’s RVMD stock sale under a Rule 10b5-1 plan?

Yes. The filing states the transaction was made pursuant to a Rule 10b5-1 instruction letter adopted on December 23, 2024. Such pre-planned arrangements automate trades, especially for purposes like covering tax obligations on equity compensation.

How many RVMD shares does Wei Lin hold after this Form 4 transaction?

After the reported sale, Wei Lin directly holds 101,366 shares of Revolution Medicines common stock. The disclosure notes this total includes 62,050 restricted stock units, which typically convert into shares as they vest over time.

How large is Wei Lin’s RVMD stock sale relative to his holdings?

Wei Lin sold 2,073 shares while remaining directly invested in 101,366 shares after the transaction. This indicates the reported sale represents a small portion of his disclosed position in Revolution Medicines common stock and related restricted stock units.

What was the sale price for Wei Lin’s RVMD shares in this filing?

The shares were sold at an average price of $99.4804 per share. This price is reported in the Form 4 as the transaction price for the 2,073 Revolution Medicines common shares sold on March 17, 2026 in the open market.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/19/2026 - 06:57 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Wei Lin

(Last) (First) (Middle)

C/O REVOLUTION MEDICINES, INC.

700 SAGINAW DRIVE

(Street)

REDWOOD CITY CALIFORNIA 94063

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Revolution Medicines, Inc. [ RVMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/17/2026		S(1)		2,073	D	$99.4804	101,366(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on December 23, 2024 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units ("RSUs") after March 15, 2025.

2. Includes 62,050 RSUs.

	/s/ Jack Anders, as Attorney-in-fact for Wei Lin	03/19/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)